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Abstract
Kaposi’s sarcoma (KS), is an AIDS-associated neoplasm caused by the KS herpesvirus
(KSHV/ HHV-8). KSHV-induced sarcomagenesis is the consequence of oncogenic viral
gene expression as well as host genetic and epigenetic alterations. Although KSHV is found
in all KS-lesions, the percentage of KSHV-infected (LANA+) spindle-cells of the lesion is var-
iable, suggesting the existence of KS-spindle cells that have lost KSHV and proliferate
autonomously or via paracrine mechanisms. A mouse model of KSHVBac36-driven tumori-
genesis allowed us to induce KSHV-episome loss before and after tumor development.
Although infected cells that lose the KSHV-episome prior to tumor formation lose their
tumorigenicity, explanted tumor cells that lost the KSHV-episome remained tumorigenic.
This pointed to the existence of virally-induced irreversible oncogenic alterations occurring
during KSHV tumorigenesis supporting the possibility of hit and run viral-sarcomagenesis.
RNA-sequencing and CpG-methylation analysis were performed on KSHV-positive and
KSHV-negative tumors that developed following KSHV-episome loss from explanted tumor
cells. When KSHV-positive cells form KSHV-driven tumors, along with viral-gene upregula-
tion there is a tendency for hypo-methylation in genes from oncogenic and differentiation
pathways. In contrast, KSHV-negative tumors formed after KSHV-episome loss, show a
tendency towards gene hyper-methylation when compared to KSHV-positive tumors.
Regarding occurrence of host-mutations, we found the same set of innate-immunity related
mutations undetected in KSHV-infected cells but present in all KSHV-positive tumors occur-
ring en exactly the same position, indicating that pre-existing host mutations that provide an
in vivo growth advantage are clonally-selected and contribute to KSHV-tumorigenesis. In
addition, KSHV-negative tumors display de novo mutations related to cell proliferation that,
together with the PDGFRAD842V and other proposed mechanism, could be responsible for
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driving tumorigenesis in the absence of KSHV-episomes. KSHV-induced irreversible
genetic and epigenetic oncogenic alterations support the possibility of “hit and run” KSHV-
sarcomagenesis and point to the existence of selectable KSHV-induced host mutations that
may impact AIDS-KS treatment.
Author summary
KSHV-infected KS lesions are composed of latently-infected cells, as well as cells express-
ing lytic genes that have been implicated in the development of the KS angioproliferative
phenotype. The existence of KS lesions with varying levels of KSHV-infected cells suggests
also the existence of virus-independent “hit and run” mechanisms of sarcomagenesis,
whereby viral infection irreversibly induce genetic or epigenetic oncogenic alterations in
host cells. We used the unique mECK36 animal model of multistep KSHV sarcomagenesis
to dissect transcriptional, genetic and epigenetic mechanisms of KSHV dependent tumor-
igenesis and during tumorigenesis following KSHV-episome loss (“hit and run”) sarco-
magenesis in an unbiased high-throughput fashion. These analyses revealed that KSHV in
vivo tumorigenesis: A) Occurs predominantly with CpG hypo-methylation of oncogenic
and differentiation pathways. B) Selects for pre-existing host mutations that allow the
KSHV oncovirus to express oncogenic lytic genes by creating permissive environment for
viral-induced innate immunity and inflammation, which provides a selective advantage in
vivo conducive to tumorigenesis. Our results highlight the mutagenic potential of KSHV
pointing to the existence in KS lesions, of KSHV-induced oncogenic host mutations that
could be selected upon treatment and impact AIDS-KS therapies.
Introduction
Human viral oncogenesis is the consequence of the transforming activity of virally encoded
oncogenes in combination with host oncogenic alterations [1]. Kaposi’s sarcoma (KS), caused
by the Kaposi’s sarcoma-associated herpes virus (KSHV), is a major cancer associated with
AIDS and is consequently a major global health challenge [2–4]. The KS tumors are character-
ized by intense angiogenesis and the proliferation of spindle cells that can affect the skin,
mucosa and viscera, causing significant morbidity [2–4]. Although KS can be treated with
anti-retroviral therapy and chemotherapy, it is estimated that more than a half of AIDS associ-
ated KS patients will not be cured [4, 5]. Understanding the interplay between viral and cellular
genes leading to KS carcinogenesis is paramount to developing rationally designed therapies
for KS.
KSHV-infected KS lesions are composed of a majority of latently infected cells, as well as
cells expressing lytic genes that have been implicated in the development of the KS angioproli-
ferative phenotype via paracrine and autocrine mechanisms [2, 3, 6–9]. Like other human
oncogenic viruses, KSHV infection alone is generally not sufficient to cause KSHV-associated
cancers, as suggested by the very low incidence of KS in the general KSHV-seropositive popu-
lation [5]. Thus, a critical question emerges: how the interplay between KSHV and host gene
expression leads to cell transformation and establishment of the KS angio-proliferative lesion.
DNA methylation at CpG dinucleotides is an epigenetic mark that has been studied exten-
sively in the context of cancer. Methylation of the cytosine residue in the CpG dinucleotide is
carried out by the DNA methyltransferases DNMT1, DNMT3a, and DNMT3b [10]. Many
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promoters contain CpG islands, and these islands are protected from methylation in normal
tissues [11]. In cancer cells, some of these CpG islands become aberrantly hyper-methylated,
and this is usually correlated with transcription repression [12]. On the other hand, global
hypo-methylation has been described in cancer cells as well [13]. DNA methylation is regu-
lated by KSHV on several levels [14]. The latency-associated nuclear antigen (LANA/ORF73)
encoded by KSHV leads to CpG methylation by interacting with the cellular de novo DNA
methyltransferase, DNMT3a, and recruiting DNMT3a to certain cellular promoters that
become methylated and repressed [15]. An additional mechanism by which KSHV might
modify the human methylome is via the Polycomb complex that creates the histone mark his-
tone H3 trimethylated on Lys27 (H3K27me3) and can direct cellular CpG methylation via its
interaction with DNMTs [16, 17]. The pattern of CpG DNA methylation in chronically
infected primary effusion lymphoma (PEL) cells and during de-novo in-vitro infection was
investigated for the KSHV episomal genome [17–19] and for the host cellular genome [20].
We have developed a cell and animal model based on mouse bone marrow cells of the
endothelial cell lineage transfected with a KSHVBac36 recombinant genome (mECK36 tumor
model) [21]. A unique feature of the mECK36 cell model is that this tumors show consistent
expression of the KS markers and that KSHV tumorigenesis is tightly linked to the presence of
the virus, since mECK36 cells that lose the viral episome can survive in culture but are not
tumorigenic [21]. Using this mECK36 model we showed that the most prominently activated
tyrosine kinase in the tumors was PDGFRA, which was activated by lytic KSHV genes such as
vGPCR via a ligand-mediated mechanism, strongly pointing to PDGFRA as a critical onco-
genic driver for KSHV sarcomagenesis [22]. More importantly, PDGFRA was prominently
expressed and phosphorylated in the vast majority of AIDS-KS tumors [22]. Upon mECK36
tumor formation in mice, explanted cells that are forced to lose the viral episome continue
being tumorigenic [23]; in part and as we have recently shown, by the irreversible in vivo
acquisition of host mutations, as the PDGFRA activating mutation D842V, the most common
PDGFRA mutation in GIST, which confers constitutive RTK activity and resistance to Imati-
nib, supporting the ideas that: 1) PDGFRA is an oncogenic driver in KSHV tumors and 2)
Oncogenic mutations may compensate for the loss of KSHV driving tumorigenesis in the
absence of the virus [22].
Reports of KS lesions displaying variable percentage of KSHV infected (LANA positive)
cells [2, 4, 22] point to the occurrence of KS-spindle cells that have lost the KSHV-episome.
This is consistent with studies showing spontaneous KSHV-episome loss in cultures, and the
proposed need of continuous re-infection in the KS-lesions and/or paracrine stimulation from
infected cells [22, 24, 25]. Yet, since our studies have shown that the KSHV-episome is retained
during tumor formation because it provides a growth advantage, the existence of KSHV-nega-
tive phospho-PDGFRA positive spindle cells in KS lesions also suggest the possibility of a
virus-independent “hit and run” mechanisms of sarcomagenesis. In this “hit and run” sce-
nario, cells would be irreversibly transformed by KSHV and would be able to sustain tumor
growth in the absence of the viral episome. This is consistent with some reports that have iden-
tified the presence of host oncogenic mutations in KS lesions [26, 27], our own results showing
that tumor cells that loose the KSHV virus have a PDGFRAD842V mutation[22], and the iso-
lation of KSHV-negative KS-cell lines such as the KS-Imm[28]. Yet, a mechanistic rationale
for a possibility of KSHV induced “hit and run” tumorigenesis have not been yet firmly estab-
lished. The combination of the mECK36 cells and their derivatives in vitro and in vivo consti-
tute a unique model to study through the use of Next Generation Sequencing not only the
transcriptional events regulated by KSHV in vitro and in vivo; but more interestingly, to define
the viral oncogenic footprint at the DNA level encompassing both changes in CpG methyla-
tion as well as mutations in transcribed genes.
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In this work, we have integrated genetic mutations analysis, changes in expression signa-
tures and methylation analysis during direct and “hit and run” KSHV oncogenesis in vitro
and in vivo, to dissect genetic and epigenetic signaling pathways in an unbiased manner in
the mECK36 mouse model of KSHV tumorigenesis [21]. Pathway analysis of differential
expressed genes (DEGs) during KSHV-dependent in vivo tumorigenesis showed KSHV lytic
gene upregulation and host DNA methylation and Epigenetic regulation as the most regu-
lated pathways during this process. Our methylation analysis data indicates that during the
development of tumors the most profound changes are towards hypo-methylation of tissue
specific genes and oncogenic signature pathways as well as for KSHV genes. On the other
hand, during viral loss and development of KSHV negative tumors the most profound
changes are towards hyper-methylation of these and additional oncogenic pathways. Muta-
tional analysis of mECK36 KSHV positive cells and tumors revealed a surprising set of muta-
tions, including mutations in inflammasome related IFN response genes, undetected in
KSHV positive cells but present in all KSHV positive tumors in the same location. This result
suggests that in the context of in vivo tumorigenesis both these mutations and the virus may
determine tumor growth. On the other hand, clustering analysis of mutations found in
KSHV negative tumors reveal a network, complementary to the PDGFRAD842V mutation,
implicated in cell proliferation. Our results have uncovered novel specific aspects of the
interplay between host oncogenic alterations and virus-induced transcriptional effects as
well as the relationship between epigenetic changes induced by KSHV infection and tumori-
genesis. These virally-induced irreversible oncogenic alterations support the possibility of a
“hit and run” KSHV sarcomagenesis which is consistent with histological findings and high-
light the existence and biological importance of KSHV-induced host mutations that may be
selected during AIDS-KS therapies and affects clinical outcomes.
Results
Animal Model of Multistep and “Hit-and-Run” KSHV sarcomagenesis
Mouse bone-marrow endothelial-lineage cells (mEC) transfected with the KSHVBac36
(mECK36 cells, abbreviated here as KSHV (+) cells) are able to form KSHV-infected tumors
in nude mice, which were thoroughly characterized as KS-like tumors [21], thus providing a
platform to dissect molecular mechanisms of tumorigenesis by KSHV. Tumors formed by
KSHV (+) cells are all episomally infected with KSHVBac36 [21](abbreviated here as KSHV
(+) tumors). When mECK36 KSHV (+) cells lose the KSHV episome in vitro by withdrawal
of antibiotic selection (abbreviated as KSHV (-) cells), they completely lose tumorigenicity
[21]. In contrast to KSHV (-) cells, cells explanted from KSHV (+) mECK36 tumors and
grown in the absence of antibiotic lose the KSHV episome (abbreviated as KSHV (-) tumor
cells), are tumorigenic and are able to form KSHV-negative tumors (abbreviated as KSHV
(-) tumors) with 100% efficiency and somehow faster than KSHV (+) cells (tumors arising in
average by day 30 versus tumors arising in average by day 47, S1 Fig). Since mECK36 cells
that lose the episome prior to in vivo growth (KSHV (-) cells) completely lose their tumorige-
nicity, these results suggest that during the process of in vivo-restricted tumorigenesis
mECK36 cells became irreversibly transformed by KSHV [21, 23]. This is likely due to host
genetic and/or epigenetic alterations accumulated during in vivo tumor growth that can
compensate for KSHV-induced tumorigenicity after loss of the KSHV episomes. We decided
to use this unique animal model of multistep KSHV sarcomagenesis (Fig 1A) to dissect tran-
scriptional, genetic and epigenetic mechanisms of KSHV-dependent and during tumorigen-
esis following KSHV-episome loss (a.k.a “hit and run”) in an unbiased high-throughput
fashion.
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RNA sequencing analysis of mECK36 model of KSHV tumorigenesis
To identify changes at the transcriptional level in our murine model of KSHV-infected cells
and tumors [21, 23], high throughput RNA sequencing was performed to identify differences
in the gene expression profile, allowing us to perform key biological comparisons (Fig 1D).
We have performed Illumina, stranded, RNA sequencing analysis of all KSHV stages of this
cell and animal model including KSHV (+) cells, KSHV (-) cells, KSHV (-) tumor cells,
KSHV (+) tumors and KSHV (-) tumors. Expression of 16,016 cellular genes in all replicates
were identified. KSHV (-) tumor cells and KSHV (-) tumors showed less than 1 KSHV read
per million reads (S2 Fig), validating them as negative for KSHV gene expression. Unsuper-
vised clustering (Fig 1B) and Multidimensional scaling plot (Fig 1C) shows how KSHV status
and tissue type cluster with each other. Interestingly, cells in vitro cluster together whether
they are KSHV (+), KSHV (-) or KSHV (-) tumor cells. On the other hand, KSHV (+) and
KSHV (-) tumors in vivo are separate from each other and from the cells in vitro (Fig 1C), fur-
ther indicating that processes occurring in vivo are predominantly distinct from in vitro and
are distinctly affected by the uniqueness of KSHV-induced tumorigenesis (Fig 1D).
To understand the effect of losing the virus in vitro and the concomitant lack in tumor for-
mation of KSHV (-) cells, we compared host gene expression profiles of KSHV (+) cells with
KSHV (-) cells (Fig 1E). As expected by the minimal phenotypic in vitro differences already
described in our previous work [21], the comparison between KSHV (+) and KSHV (-) cells
showed only 143 differentially expressed genes (DEG) (Fig 1D, Fig 1F and S1 Table, Tab-A).
Pathway analysis of these DEGs showed changes on Cellular senescence, VEGF signaling [21],
FGF signaling and p53 signaling (Fig 1G and S1 Table, Tab-FEA1). The small number of host
DEG between tumorigenic KSHV (+) cells and non-tumorigenic KSHV (-) cells in vitro high-
lights the importance of the in vivo KSHV lytic switch during the process of tumor formation
that was formerly characterized as “in vivo-restricted oncogenesis” [21].
To deepen our understanding of the mechanism of KSHV mediated oncogenesis in vivo,
we analyzed the KSHV gene expression profiles of KSHV (+) cells and KSHV (+) tumors (Fig
2A). Multidimensional scaling plot and heat map analysis in Fig 2B and 2C shows that these
two stages (in vitro versus in vivo) bear two different KSHV gene expression profiles. KSHV
(+) tumors showed an increased expression of lytic KSHV genes (ORF75, ORF-K15, ORF74,
ORF-K2), including several well-characterized viral oncogenes such as vGPCR (ORF74), vIL6
(ORF-K2) and K15 (Fig 2C and S1 Table, Tab-B). To better understand and visualize these dif-
ferences we performed a histogram showing transcript coverage for KSHV encoded genes in
KSHV (+) tumors and KSHV (+) cells (Fig 2D). This result corroborates the up-regulation of
KSHV lytic genes found in vivo, previously described for this model of KSHV tumorigenesis
using real-time qRT-PCR array [21, 22] throughout the process of mECK36 tumorigenesis.
The lack of RNA-sequencing signal in the region 35-69kb (Fig 2D) suggested a deletion of this
portion of the KSHV episome which was later confirmed by qPCR. These type of deletions can
occur in Bac36; yet, this did not impacted the capacity of the KSHVBac36 to form tumors [21].
Moreover, we performed KSHV-LANA IFA, in KSHV (+) tumors, and we found the typical
speckle nuclear staining pattern indicative of KSHV episomal infection (S3 Fig).
Fig 1. Genome-wide analysis of host transcripts by RNA deep sequencing. (A) Schematic representation of the animal Model of Multistep KS Carcinogenesis. (B)
Unsupervised hierarchical clustering of the host transcriptome. (C) Multidimensional scaling plot of the host transcriptome showing the distance of each sample from
each other determined by their leading logFC. The leading logFC is a distance metric that represents the average (root mean square) of the largest absolute logFC
between each pair of samples. (D) Number of differential expressed genes (DEGs) in key biological comparisons that were detected by RNA-sequencing analysis of:
two KSHV (+) cells, two KSHV (-) cells, six KSHV (+) tumors, two KSHV (-) tumor cells and three KSHV (-) tumors. (E) Schematic representation of the
comparison between KSHV (+) cell and KSHV (-) cell. (F) Volcano plot showing 144 differentially expressed genes (DEGs) analyzed by RNA-Sequencing between
KSHV (-) cells and KSHV (+) cells in vitro. 70 genes were down-regulated and 73 gees were up-regulated in KSHV (-) cells. (G) Functional enrichment analysis based
on the 144 genes differentially expressed among KSHV (-) cells and KSHV (+) cells in vitro.
https://doi.org/10.1371/journal.ppat.1008589.g001
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Fig 2. Transcriptional effects mediated by KSHV and by environmental cues in vivo. (A) Scheme of the comparison between KSHV (+) cell and KSHV (+)
tumor. (B) Multidimensional scaling plot for KSHV gene expression of KSHV (+) cells and KSHV (+) tumors. (C) Heat map for fold change expression of
KSHV-encoded genes based on analysis of RNA sequencing data between KSHV (+) cells and KSHV (+) tumors. Only KSHV genes with statistical significance
(p<0.05) are shown. (D) Histogram showing transcript coverage for KSHV-encoded genes, comparison of the transcription profiles of KSHV (+) cells and
KSHV (+) tumors. Transcriptional levels of viral genes were quantified in reads per kilo base of coding region per million total read numbers (RPKM) in the
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To study and compare transcriptional effects in the host genes induced by in vivo environ-
mental cues both in KSHV-dependent tumorigenesis and during tumorigenesis following
KSHV-episome loss settings, we compared gene expression profiles of KSHV (+) cells versus
KSHV (+) tumors (Fig 2E) with that of KSHV (-) tumor cells versus KSHV (-) tumors (Fig 2F
and 2G). Both comparisons showed around 3000 host DEGs (Fig 1D and S1 Table, Tab-B and
Tab-C respectively), further indicating the impact of in vivo growth conditions on host gene
expression. Pathway analysis of these DEGs showed DNA methylation and Epigenetic regula-
tion together with Immune System related pathways as the most differentially regulated when
KSHV (+) cells form KSHV (+) tumors (Fig 2H and S1 Table, Tab-FEA2). Interestingly, the
transition in vitro to in vivo but in the absence of KSHV, when KSHV (-) tumor cells form
KSHV (-) tumors did not show DNA methylation and Epigenetic related regulation pathways
as differentially regulated. Instead they showed Immune and Metabolic related pathways as
the most differentially regulated pathways (Fig 2I and S1 Table, Tab-FEA3), further indicating
the importance of DNA methylation and Epigenetic regulation during KSHV-dependent
transformation and tumorigenic growth.
To study the impact of KSHV infection within KSHV (+) tumors we compared the tran-
scriptome of KSHV (+) tumors with KSHV (-) tumors (Fig 3A), which are both driven by
PDGFRA signaling [22]. In KSHV infected tumors PDGFRA is activated by KSHV-induced
ligands (PDGFA and B), while in KSHV (-) tumors PDGFRA bears a heterozygous constitu-
tively activated mutated form (D842V)[22]. Fig 3B shows that gene expression profiles differ-
ences in KSHV (+) compared to KSHV (-) tumors ascends to 4019 DEG (Fig 1D and S1 Table,
Tab-D), illustrating the impact of in vivo KSHV gene expression on host gene expression.
Remarkably, pathway analysis showed DNA methylation and Epigenetic regulation of gene
expression as the most differentially-regulated pathway between KSHV-positive and KSHV-
negative tumors (Fig 3C and S1 Table, Tab-FEA4). We used the CIBERSORT in silico method
[29] to determine absolute immune cell fractions within the tumor microenvironment of
KSHV-positive and KSHV-negative tumors. We found the occurrence of Immune cells infil-
tration (B-cells, neutrophils, NK cells) in KSHV (+) tumors (Fig 3D) which reflects the contri-
bution of the inflammatory infiltrate to KSHV driven tumors by innate immunity
mechanisms that can operate even in athymic mice. Although both KSHV (+) and KSHV (-)
tumors are highly vascularized, the CIBERSORT showed also a remarkable increase in endo-
thelial cell component which is consistent to the ability of KSHV to upregulate angiogenesis
and endothelial specific genes [21] and induce transendothelial differentiation [30, 31].
Methylation footprint of KSHV infection in the context of KSHV
oncogenesis
KSHV is a reprogramming virus that encodes viral genes with powerful epigenetic regulating
activities that affect the host. In particular, KSHV could affect DNA CpG methylation on the
cellular genome, which contribute to cellular transformation and tumorigenicity. A portion of
the DNA CpG methylated sites are expected to remain even after KSHV episomal loss leading
to irreversible epigenetic regulatory changes affecting host gene expression. We showed in Figs
sample. The y-axis represents the number of reads aligned to each nucleotide position and x-axis represents the KSHV genome position. (E) Volcano plot
showing 3674 differentially expressed genes (DEGs) analyzed by RNA-Sequencing between KSHV (+) tumors and KSHV (+) cells. 1211 genes were down-
regulated and 2462 genes were up-regulated in KSHV (+) tumors. (F) Scheme of the comparison between KSHV (-) cell and KSHV (-) tumor. (G) Volcano plot
showing 3392 differentially expressed genes (DEGs) analyzed by RNA-Sequencing between KSHV (-) tumor cells and KSHV (-) tumors. 2112 genes were
down-regulated and 1279 genes were up-regulated in KSHV (-) tumor cells. (H) Functional enrichment analysis based on the 3674 genes differentially
expressed among KSHV (+) cells and KSHV (+) tumors. (I) Functional enrichment analysis based on the 3392 genes differentially expressed among KSHV (-)
tumor cells and KSHV (-) tumors.
https://doi.org/10.1371/journal.ppat.1008589.g002
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2 and 3 the importance of DNA methylation related pathways in the process of KSHV-depen-
dent tumorigenesis. DNA methylation analysis of the cells and tumors generated from this
multistep model, affords unique biological comparisons and the possibility of studying the
footprints of KSHV infection at the level of the CpG methylation landscape. This afforded
remarkable and unique observations on the effects of KSHV infection in the host and some of
the molecular mechanisms underpinning KSHV oncogenicity. To follow genome wide DNA
methylation, DNA from cells grown in culture or during tumorigenic growth in mice, was
subjected to enrichment on Methylated DNA binding beads (MBD2-beads) and the eluted
DNA served for library preparation and next-generation-sequencing. The sequenced reads
were aligned to the mouse (mm10) genome, and enriched peaks were identified, and anno-
tated. During the transition between KSHV (+) cells and their KSHV (+) tumors (Fig 4A),
where we showed a KSHV in vivo lytic switch and DNA methylation as the most differentially
regulated pathway (Fig 2), we identified 4515 differentially hypo-methylated regions and 3525
Fig 3. Transcriptional effects of KSHV infection in KSHV-positive and KSHV-negative tumors. (A) Scheme of the comparison between KSHV (+)
tumors and KSHV (-) tumors. (B) Volcano plot showing 4020 differentially expressed genes (DEGs) analyzed by RNA-Sequencing between KSHV (-)
tumors and KSHV (+) tumors. 2087 genes were down-regulated and 1932 genes were up-regulated in KSHV (-) tumors. (C) Functional enrichment analysis
based on the 4020 genes differentially expressed among KSHV (+) tumors and KSHV (-) tumors. (D) CIBERSORT in silico method to determine absolute
immune cell fractions within the tumor microenvironment of KSHV-positive and KSHV-negative tumors.
https://doi.org/10.1371/journal.ppat.1008589.g003
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Fig 4. Methylation footprint of KSHV infection in the context of KSHV oncogenesis. (A) Scheme of the comparison between KSHV (+) cell and KSHV (+)
tumor. (B) The number of differentially methylated regions. Red represents hyper-methylation, and blue represents hypo-methylation. (C) Differentially
methylated promoters (-1500 to +200 relative to TSS). Red represents hyper-methylation, and blue represents hypo-methylation. (D) Differentially methylated
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differentially hyper-methylated regions (Fig 4B, S2 and S3 Tables). In order to correlate differ-
ential methylation with gene expression we generated a list of differentially methylated pro-
moter (-1500 to +200) regions. Here, clear preferential for hypo-methylation was observed,
with 1724 hypo-methylated and 590 hyper-methylated promoters (Fig 4C, S2 and S3 Tables).
Analysis of these hypo-methylated promoter peaks on the GREAT (Genomic Regions Enrich-
ment of Annotations Tool, (http://great.stanford.edu/public/html/index.php) platform identi-
fied biological process for pancreatic A cell, astrocyte, dendritic spine, glial cell,
enteroendocrine cell, and eye differentiation. In other words, hypo-methylation of many tissue
specific promoters, that are expected to be hyper-methylated in the endothelial-lineage cells
infected by the virus, and may suggest loss of cell identity/ de-differentiation. These hypo-
methylated promoter peaks also identified oncogenic signatures, for genes up-regulated by
NF-kB, K-RAS, IL-2, and by knockdown of EED. No terms were identified in biological pro-
cesses and oncogenic signatures for hyper-methylated promoter peaks (S4 Table). Our data
indicates that during the development of tumors and KSHV in vivo lytic switch the most pro-
found changes are towards hypo-methylation of tissues specific genes and oncogenic signature
pathways. Next, we combined our differential promoter methylation data with gene expression
data from Fig 2. This analysis identified 340 hypo-methylated and up-regulated genes, and
only 6 hyper-methylated and repressed genes (Fig 4D and S5 Table). Here again, the prefer-
ence towards hypo-methylation and up-regulation was highlighted. The heat map of several
genes that were both hypo-methylated and up-regulated in KSHV (+) tumors is presented (Fig
4E). These include the two Platelet Derived Growth Factors Pdgfa, Pdgfb and their receptor
Pdgfra. In a recent study, we have shown that the KSHV-ligand mediated activation of the
PDGF signaling pathway is critical for KS development [22]. Here, we also identified hypo-
methylation and up-regulation of Angiopoietin 2 (Angpt2) and 4 (Angpt4) that in combina-
tion with VEGF facilitate endothelial cell migration and proliferation, to promote angiogene-
sis. In addition, hypo-methylation and up-regulation of several neuronal specific, Pax6 and
Shank3 genes, linking KSHV-associated tumorigenesis with loss of cell identity. Chromosome
view of two genes that we detected hypo-methylation in the regulatory region, clearly show
that the loss of DNA methylation is specific in the gene promoter around the transcription
start site (Fig 4F). We validated our global methylation analysis by performing qPCR with spe-
cific primers for several differentially methylated promoter regions (S4A Fig). Methylation
analysis of the KSHV genome showed also a trend to more hyper-methylation in KSHV (+)
cells than in KSHV (+) tumors (Fig 4G) correlated with an increase in KSHV viral gene expres-
sion in these KSHV (+) tumors (Fig 2). Gene ontology analysis on STRING (https://string-db.
org) for the list of hypo-methylated and up-regulated genes, identified the following cellular
pathways; Ras signaling, cytokine receptors, PI3K-Akt signaling, Rap1 signaling, calcium sig-
naling, focal adhesion, and ECM-receptor interaction (Fig 4N).
promoters that were correlated with gene expression. Red represents hyper-methylation, and blue represents hypo-methylation. (E) Heat map of selected genes
with differentially methylated promoters that were correlated with gene expression in the RNA-sequencing analysis. (F) Chromosome view of gene promoters
which were differentially hypo-methylated. (G) Evaluation of KSHV methylation was performed on MBD2-beads enriched DNA followed by qPCR of the
methylated region in ORF64. Percentage of un-methylated (gray) and methylated (black) fractions are presented. (H) Scheme of the comparison between
KSHV (+) tumors and KSHV (-) tumors. (I) The number of differentially methylated regions. Red represents hyper-methylation, and blue represents hypo-
methylation. (J) Differentially methylated promoters (-1500 to +200 relative to TSS). Red represents hyper-methylation, and blue represents hypo-methylation.
(K) Differentially methylated promoters that were correlated with gene expression. Red represents hyper-methylation, and blue represents hypo-methylation.
(L) Heat map of selected genes with differentially methylated promoters that were correlated with gene expression in the RNA-sequencing analysis. (M)
Chromosome view of gene promoters which were differentially hypo-methylated. (N) Gene ontology analysis on STRING identified pathways that were
induced during KSHV-dependent tumorigenesis. Common pathways that were repressed following viral loss are marked in pink. (O) Gene ontology analysis
on STRING identified pathways that were repressed during tumorigenesis following KSHV-episome loss. Common pathways that were induced following
tumorigenesis with the virus are marked in pink. (P) KSHV-LANA, total and phospho-PDGFRA together with PDGFA and PDGFB levels were analyzed by
immunoblotting in KSHV (+) cells, KSHV (+) tumors, KSHV (-) tumor cells and KSHV (-) tumors. Actin was used as loading control.
https://doi.org/10.1371/journal.ppat.1008589.g004
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Next, we followed the process where KSHV (+) tumor cells have lost the viral episome by
growth without antibiotic selection and re-grown as tumors in mice, forming KSHV (-)
tumors (Fig 4H). We identified 8402 differentially hyper-methylated regions and 1656 differ-
entially hypo-methylated regions, with a clear preference for hyper-methylation (Fig 4I, S6
and S7 Tables). When the list of differential methylation was limited to promoter (-1500 to
+200) regions, again a clear preferential for hyper-methylation was observed with 2048 hyper-
methylated and only 347 hypo-methylated promoters (Fig 4J,S6 and S7 Tables). While in the
transition between KSHV (+) cells to KSHV (+) tumors hypo-methylation was more signifi-
cant (Fig 4B–4D), in the comparison between KSHV (+) tumors with KSHV (-) tumors hyper-
methylation governs (Fig 4I–4K). Analysis of these hyper-methylated promoter peaks on the
GREAT (Genomic Regions Enrichment of Annotations Tool, (http://great.stanford.edu/
public/html/index.php) platform identified biological process for actin filament organization,
regulation of cell fate, cell-substrate and cell-matrix adhesion, phagocytosis, epithelial cell dif-
ferentiation, smooth muscle contraction, and Rac protein signal transduction. The pathways
involved in BCR (B-cell receptor) signaling, RXR (retinoid x receptor) and RAR (retinoic acid
receptor) signaling. These hyper-methylated promoter peaks also identified oncogenic signa-
tures for SELL, MYD88, RAGE, LTK, and PML. No terms were identified in these categories
for hypo-methylated promoter peaks (S8 Table). Our data indicates that during KSHV loss
and development of KSHV (-) tumors the most profound changes are towards hyper-methyla-
tion. When we combined our differential promoter methylation data with gene expression
data from Fig 3, we identified, 272 hyper-methylated and down-regulated genes, and only 21
hypo-methylated and up-regulated genes (Fig 4K and S5 Table). Here again, the preference
towards hyper-methylation and down-regulation was highlighted. The heat map of several
genes that were both hyper-methylated and down-regulated in KSHV (-) tumors are presented
(Fig 4L). These include some examples of genes that were hypo-methylated and up-regulated
during the transition from KSHV (+) cell to KSHV (+) tumor and are now hyper-methylated
and down-regulated, such as Angpt4, Pdgfb, and Shank3. The negative regulators of the WNT
signaling, APC and APC2, and Tle2 a transcriptional corepressor that Inhibits the Wnt signal-
ing via interaction with CTNNB1 and TCF. This highlights the need to activate the Wnt signal-
ing by other means, following the loss of the virus. Down-regulation for the positive regulators
of the epithelial/endothelial to mesenchymal transition, Zeb1 and Zeb2, that are in agreement
with a shift backward from mesenchymal to epithelial/endothelial following viral loss. In addi-
tion, regulators of RNA interference, Ago2, and regulators of chromatin organization, poly-
comb catalytic subunit Ezh1. Chromosome view for examples of two genes with hyper-
methylation in the regulatory region, clearly show increase in DNA methylation in the gene
promoter (Fig 4M). We validated our global methylation analysis by performing qPCR with
specific primers for several differentially methylated promoter regions (S4B Fig). Gene ontol-
ogy analysis on STRING (https://string-db.org) for these hyper-methylated and down-regu-
lated genes identified genes in the following cellular pathways (KEGG); PI3K-Akt signaling,
Rap1 signaling, focal adhesion, ECM-receptor interaction, adrenergic signaling in cardiomyo-
cytes, cholinergic and glutamatergic synapse (Fig 4O). Interestingly, pathways including
PI3K-Akt signaling, Rap1 signaling, axon guidance, microRNA in cancer, focal adhesion, and
ECM-receptor interaction were upregulated and their gene promoters were hypo-methylated
during tumorigenesis with the virus, and these same pathways were down-regulated and gene
promoters were hyper-methylated during tumor formation following loss of the virus (Fig 4N
and 4O). This indicates that viral proteins/RNAs are necessary for both the hypo-methylation
and up-regulation, but also for the maintenance of these pathways’ activation. These marks are
eliminated following viral loss. In order to validate our RNA-sequencing, pathway analysis and
DNA methylation data we performed Western blot assays to study the PDGFRA activation
PLOS PATHOGENS Mutational and DNA-methylation tumorigenic footprints support KSHV hit and run oncogenesis
PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1008589 June 30, 2020 12 / 26
axis (Fig 4P). We found PDGFRA activation and upregulation of its ligands in the transition in
vitro to in vivo, when KSHV (+) cells form KSHV-dependent tumors as previously shown
[22]. This upregulation correlates with our methylation and expression data showing hypo-
methylation and upregulation of Pdgfa, Pdfgb and Pdfgra in KSHV (+) tumors (Fig 4E). On
the other hand, in the transition in vitro to in vivo but in absence of KSHV, when tumor cells
that lost the KSHV episome form KSHV (-) tumors, we did not found increase in the activa-
tion of PDGFRA signaling, with very low level of the PDGF ligands (Fig 4P). This data corre-
lates with the methylation and expression data showing hyper-methylation and
downregulation of Pdgfb in KSHV (-) tumors when compared with KSHV (+) tumors (Fig
4L), as well as with previous report showing that in KSHV (-) tumors PDGFRA bears a hetero-
zygous constitutively activated mutated form (D842V) [22].
Analysis of the mutational landscape
KSHV-negative tumors belong to the same cell lineages as mECK36 tumors and share a signifi-
cant overlap with the human KS transcriptome [23]. Therefore, they are the best available con-
trol to be used in combination with KSHV-positive tumors, which are a model of KSHV-
dependent tumorigenesis [21], to assess KSHV-specific biology [23]. As discussed above; in
contrast to KSHV (+) cells that when they lose the KSHV episome lose their tumorigenicity,
explanted KSHV (+) tumor cells that lose the episome are strongly tumorigenic. This likely indi-
cates that during in vivo tumorigenic growth mECK36 cells acquire irreversible host oncogenic
alterations, such as oncogenic mutations, that are able to convey tumorigenicity in the absence
of KSHV. We have previously found one such mutation as KSHV (-) tumors and cells had a het-
erozygous D842V mutation in the tyrosine kinase (TK) domain of the PDGF receptor alpha
[22]. In KSHV (+) tumors and cells, PDGFRA was wild-type and activated by its ligands
PDGFA/B that were induced via a KSHV-dependent mechanism [22]. We found that the
PDGFRAD842V mutation, which was described in GIST as a driver mutation, also was a driver
mutation in our KSHV (-) tumors further supporting the idea that PDGFRA is a key oncogenic
driver in KSHV tumors, that in its activated mutated form can compensate for KSHV loss [22].
This findings also suggested the possibility that such scenario may occur in KS lesions in which
host oncogenic alterations induced through KSHV oncogenic activity may compensate for
KSHV loss. In fact, we were able to identify skin AIDS-KS biopsies in which only a small per-
centage of phospho-PDGFRA positive KS spindle-cells were LANA positive (Fig 5A). The exis-
tence of these KS lesions with low levels of KSHV infected cells, together with other reports
showing that the proportion of infected cells is variable in KS lesions [2, 4], suggests the possibil-
ity of a virus-independent “hit and run” mechanisms of sarcomagenesis whereby the KSHV
oncovirus is able to induce irreversible genetic and epigenetic alterations. To assess the possibil-
ity that during in vivo tumorigenic growth, KSHV driven mutagenic mechanisms such as oxida-
tive stress and DNA damage repair impairment [23, 32, 33] may inflict mutagenic damage in
the host genome, we compared the levels of DNA repair foci between mECK36 KSHV (+) cells
and KSHV bearing mECK36 cells “just explanted” from tumors. Fig 5B shows that KSHV (+)
cells explanted from KSHV (+) tumors have much higher levels of ƴH2AX phosphorylation
than their cultured counterparts, which indicates that during the tumor growth KSHV (+) cells
increased their foci of DNA repair. This suggests that during tumorigenic in vivo growth, there
is an increase in DNA damage and; thus, KSHV (+) cells explanted from tumors are likely to
have acquired irreversible host tumorigenic mutations that may contribute to overall tumor
growth and may allow explanted cells to form tumors in the absence of KSHV.
In order to analyze mutations acquired during in vivo tumorigenic growth we used the
RNA-sequencing data and the Genome Analysis Toolkit (GATK) workflow to call for host
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mutations (Fig 5C). Detailed analysis of the mutational landscape of KSHV (+) and KSHV (-)
cells and tumors was carried out taking in account the following criteria: 1) Transcripts have
to be expressed in all compared samples (seq. depth >5). 2) We selected highly mutated genes:
either one homozygous or two heterozygous mutations in various locations of the gene. One
remarkable finding was that there were set of genes mutated in all six KSHV (+) tumors, but
not in the KSHV (+) cell cultures (Tumor-associated mutations, Fig 5D and S9 Table). In-
terestingly, 56 genes had recurrent mutations in the exact same position. The only possible
explanation for this finding is that these mutations were present already in the polyclonal pop-
ulation of KSHV (+) cells but were not detected by the RNA-sequencing analysis since they
were present in a minimal percentage of cells. Yet, the consistent appearance of mutations in
exactly the same gene locations in all the tumors once the cells grew in vivo indicates that these
mutations were enriched as they likely provided an in vivo survival advantage. Moreover,
many of the mutations that “appear” in all KSHV (+) tumors “disappear” in explanted cells
only to “reappear” when these KSHV (-) tumor cells are re-injected in vivo to form KSHV (-)
tumors, further showing the reversibility of the selection process once the polyclonal popula-
tion of cells are explanted and how selection operates again when these cells grow back in vivo
(Fig 5D). Interestingly, network analysis of these mutations showed that many of them corre-
sponded to innate immune genes including TRIM12, several members of the IFI family which
are IFN inducible genes (Mnda, IFI203, IFI202) and a series of genes implicated in cytoplasmic
DNA sensing and inflammasome/IFN activation (Fig 5E). The analysis of these mutations
points to KSHV tumorigenesis as a complex combination of effects from lytic KSHV oncogen-
esis combined with host mutations in innate immune genes that enable expression of those
viral oncogenic genes and repress mechanism of innate immunity against the virus allowing
KSHV-dependent tumorigenesis to progress. We found another very interesting set of muta-
tions which appear de novo and manifested only on mECK36 explanted tumor cells that have
lost the virus (KSHV (-) tumor cells) and the tumors they form (KSHV (-) tumors) (KSHV (-)
Tumor associated mutations, Fig 5D and S9 Table). These were acquired and are the conse-
quence of KSHV oncogenicity during in vivo tumors growth. It is unlikely that they are solely
a product of selection upon culture in the absence of antibiotic in vitro since KSHV (-) cells
that were generated in a similar way that KSHV (-) tumor cells are not tumorigenic and freshly
explanted KSHV infected tumor cells show increased levels of DDR foci consistent with an in
vivo mutagenesis scenario (Fig 5B). Clustering analysis of these mutations reveal a network
comprising the already described PDGFRA D842V, Pak1 (a Rac1 activated kinase) and
Nucleolin mutations implicated in cell proliferation (Fig 5F). It is possible that these mutations
would be able to contribute driving tumorigenesis compensating for KSHV loss. In addition to
the driver mutation PDGFRAD842V which we previously were able to target in KSHV (-)
tumors with the potent PDGFRA inhibitor Sunitinib [22], we analyzed all the mutated genes
found in our analysis using the IntOGen-mutations platform to identify genes with driver
mutations [34]. Interestingly, in addition to PDGFRA we found four genes previously shown
to be driver mutations in different cancers: SETD2, FAT4, TRIP11 and PPP3CA (Fig 5D,
highlighted genes).
Fig 5. Analysis of the mutational landscape. (A) Staining of AIDS-KS biopsies from an ACSR tissue microarray (TMA) showing high phospho-
PDGFRA and low LANA staining in two characteristic samples. (B) Immunofluorescence analysis of ƴH2AX expression (red) was performed on
GFP-positive KSHV (+) cells and GFP-positive KSHV (+) cells explanted from tumor; nuclei were counterstained with DAPI (blue). (C) The
GATK workflow used to call host mutations. (D) Heat map of the most frequently and highly mutated genes. Genes with driver mutations in
cancer are highlighted. (E) Network analysis of mECK36 KSHV (+) tumors associated mutations (tumor associated mutations). (F) Network
modeling with genes mutated in KSHV (-) tumor associated mutations.
https://doi.org/10.1371/journal.ppat.1008589.g005
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Discussion
Viral oncogenesis is the consequence of dysregulation of host signaling proliferation and sur-
vival pathways caused by viral oncogenes, in combination with host oncogenic alterations cat-
alyzed by viral infection, that are accumulated through the process of oncogenesis. This
“transforming capacity” of viral infection supports the possibility of “hit and run” scenario,
whereby episomal viruses that cause cellular transformation through a irreversible genetic
alteration—the initial “hit,”—can be lost—they could “run”—since the transformed phenotype
would be maintained by the host oncogenic alterations [33]. The hit-and-run hypothesis pro-
poses scenarios in which cumulative host mutations can allow viral genomes to be lost entirely,
such that cancers remaining virus-positive represent only a fraction of those to which infection
contributes [35]. We have generated a unique multistep KSHV tumorigenesis model in which
cells explanted from a KSHV(+) PDGFRA (+) tumor that lose the episome can form KSHV (-)
tumors driven by host mutations such as the PDGFRA-D842V [22, 23]. We hypothesize that
these KSHV (-) tumors may represent KSHV LANA (-) PDGFRA (+) KS spindle cells that
composed many KS tumors, particularly those where KSHV infected cells are a minority of
tumors cells [2, 4, 22]. We took advantage of this model and NGS to interrogate the transcrip-
tional, genetic and epigenetic (CpG island methylation) landscape upon KSHV tumor forma-
tion and upon KSHV-loss in cells and tumors.
We identified DNA methylation and Epigenetic regulation as the most relevant pathways
involved in KSHV-dependent tumorigenesis occurring along with up-regulation of KSHV
lytic genes. In contrast, during tumorigenesis following KSHV-episome loss we found
Immune and Metabolic regulation as the most relevant pathways involved in this process. We
found hypo-methylation of tissue specific genes and oncogenic signature pathways occurring
along KSHV-dependent tumorigenesis. Conversely, during viral loss and development of
KSHV negative tumors the most profound changes were towards hyper-methylation of these
and additional oncogenic pathways. In analyzing the mutational landscape we found a set of
mutations in genes regulating viral DNA and innate immunity, which were absent in KSHV-
infected cells but present in all KSHV-infected tumors. This indicates that KSHV tumorigene-
sis not only selects for the presence of the virus but also pre-existing host mutations that only
provide a selective advantage in vivo. Moreover, we found that KSHV oncogenesis also
induced the accumulation of mutations implicated in cell proliferation which appear de novo
and manifested only on KSHV (-) tumor cells and KSHV (-) tumors, these mutations would
be responsible to be driving tumorigenesis compensating for KSHV loss. This mechanism
could work together with other previously described mechanisms showing that virus-induced
epigenetic alterations may continue to support proliferation and survival of spindle cells after
loss of KSHV [24].
We have previously shown, by real-time qRT-PCR, that KSHV tumorigenesis in the
mECK36 mouse KS-like model occurs with concomitant up-regulation of KSHV lytic genes
and angiogenic ligands/receptors [21, 22]. After completion of all our metadata analysis, we
confirm a deletion between positions 35–69 kb in the KSHV-Bac36 genome. Genome instabil-
ity has been documented for the Bac36 [36]; yet it does not affected the ability of the Bac36 to
be tumorigenic in the mECK36 cells, which reflects also the fact that defective KSHV genomes
—that have been found in KS lesions—are oncogenic [37]. Although it could pose a limitation
in some of the potential uses of our model, the deletion of the KSHV genome did not impacted
the capacity of the KSHVBac36 to form tumors. Furthermore, findings on our recently pub-
lished work [38] using a novel model of de novo KSHV oncogenesis based on infection of
PDGFRA-positive mesenchymal stem cell progenitors with rKSHV219 suggest that the dele-
tion occurred in a region of the KSHV genome that is least involved in tumorigenesis. We
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showed by RNA-sequencing in KS-like mouse tumors that indeed this 35-69kb portion of the
KSHV episome is the area of the KSHV genome least expressed in KSHV-induced tumors
[38]. Therefore, except for the inability of our model to capture the effects of the KSHV gene
expression in this region, the deletion in KSHVBac36 do not affect our capability to study
KSHV-dependent tumorigenesis and the effect of KSHV loss. Another indication of the bio-
logical value of our mouse system is the fact that allowed us to identify PDGFRA as the main
driver of KSHV sarcomagenesis [22]. Importantly, our present RNA-sequencing analysis also
showed up-regulation of all the members of the PDGF family members in KSHV (+) tumors
together with an increase in KSHV lytic gene expression. Moreover, pathway analysis of differ-
entially expressed genes (DEGs) showed that DNA methylation and Epigenetic regulation are
the most relevant pathways involved in KSHV-dependent tumorigenesis (Fig 2H). This indi-
cates that, as expected for a virus with strong epigenetic reprogramming capacities, KSHV-
induced tumorigenesis is tightly linked to epigenetic regulation of host gene expression. This
is also reinforced by the fact that during tumorigenesis following KSHV-episome loss this pro-
cess occurred predominantly by Immune and Metabolic pathway regulation (Fig 2I). Epige-
netic processes have been heavily implicated in the development of cancer, in which
repression or silencing of tumor suppressor genes is remarkably common [14]. Interestingly,
KSHV (+) tumors showed up-regulation of Immune cells infiltration and endothelial cell com-
ponents when compared with KSHV (-) tumors by CIBERSORT analysis, which is consistent
with the recruitment of inflammatory cells in the context of viral tumorigenesis and to the abil-
ity of KSHV to up-regulate angiogenesis respectively.
Our system allowed following whole genome CpG methylation of the host during tumori-
genesis by KSHV. During KSHV-dependent tumorigenesis, we observed clear preference
towards hypo-methylation in gene promoters. It is important to mention that the goal of this
study was to identify the changes during tumorigenesis and not following infection, therefore
the hyper-methylation immediately following infection is already present in the KSHV (+)
cells. These results are in agreement with a previous study [20] that tried to address this ques-
tion indirectly by comparing KSHV-negative BJAB to de-novo infected BJAB (BJAB.219) or to
chronically infected PEL cells, and detected very similar hyper-methylation between de-novo
infection and PEL, but dramatic difference towards hypo-methylation in PEL. While our study
directly evaluates the methylation changes during transformation, both studies support the
notion that hypo-methylation is the major epigenetic change during this process. Interestingly,
hypo-methylation is also the major process during transformation of naïve B-cells following
Epstein-Barr virus (EBV) infection [39].
CpG DNA methylation is an epigenetic mark that can be faithfully maintained between
generations [40, 41]. Therefore, CpG methylation changes imposed by viral infection are
expected to maintain following viral clearance. Our findings indicate that indeed some methyl-
ation changes are maintained following viral clearance, but some are lost, suggesting that the
presence of viral encoded proteins or RNAs are necessary to maintain these epigenetic
changes. In the case of KSHV (+) tumors these gene promoters are hypo-methylated and the
genes are expressed, and in KSHV (-) tumors upon virus loss, these promoters becomes meth-
ylated again and repressed.
During the development of tumors following loss of KSHV we observed hyper-methylation
of three main groups of genes: 1) genes that were previously hypo-methylated by the virus and
viral gene products need to be expressed in order to keep these genes active, therefore viral loss
leads to re-repression and hyper-methylation. 2) Oncogenic pathways that are activated by the
virus and are essential for tumor growth, upon viral loss the tumor cells need to find alternative
ways to activate these pathways. Nice example is the Wnt signaling that is activated by KSHV
encoded LANA [42]. During tumor growth without the virus we detected hyper-methylation
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of three repressors of the Wnt signaling, the tumor suppressors and the antagonists of the Wnt
signaling, APC [43] and APC2 [44], and Tle2 a transcriptional corepressor that binds to and
Inhibits the transcriptional activation of CTNNB1 and TCF family members that mediate the
Wnt signaling [45]. Moreover, we found PDGF signaling members (Pdgfa, Pdgfb and
Pdgfra) also hypo-methylated and up-regulated in these transitions as well, correlated with
PDGFRA signaling activation (Fig 4P) and further illustrating another KSHV-dependent
mechanism to maintain the activation of this oncogenic signaling pathway. 3) Changes due to
cell differentiation/de-differentiation. KSHV was found to induce endothelial to mesenchymal
(EdMT) transition [30, 46]. In agreement with this transition, we observed hypo-methylation
of ZEB1 during tumor development in KSHV infected cells. On the other hand, when tumors
develop in the absence of the virus, we observed hyper-methylation of ZEB1 and ZEB2, which
indicates a shift backwards from mesenchymal to endothelial (MTEd) transition.
KSHV is a reprogramming virus encoding genes with powerful epigenetic regulatory abili-
ties. Characterization of the CpG methylation footprint of KSHV infection showed a tendency
towards hypo-methylation concomitant with KSHV tumorigenesis occurring along the up-
regulation of KSHV lytic genes and hyper-methylation in comparing tumors infected versus
un-infected with KSHV. The methylation level of the genome is controlled by two opposing
activities; DNA methyltransferase, DNMT1, DNMT3a, and DNMT3b, and DNA de-methyl-
ases, TET1, TET2 and TET3. Our analysis during tumor development of KSHV (+) tumors
detected promoter hypo-methylation and up-regulation of the demethylase Tet2 gene. This
observation can provide a mechanistic explanation for the hypo-methylation that occurs dur-
ing tumorigenesis. These results showed the importance of DNA methylation regulation in the
process of KSHV-dependent oncogenesis.
The existence of spindle-shaped cells within a KS lesion positive for phospho-PDGFRA and
negative for KSHV LANA would exemplify a LANA-negative proliferative spindle cells which
are not rare in KS, since KS lesions with varying levels of KSHV infected cells, ranging from
<10% to>90% of the total cell population in the KS lesions have been reported [2, 4]. This,
together with the observation of spontaneous KSHV episome loss in cultures of KS spindle-
cells and the isolation of tumorigenic KSHV (-) KS spindle-cells [28], suggests the existence of
virus-independent “hit and run” mechanisms of sarcomagenesis whereby the KSHV oncovirus
is able to induce irreversible genetic and epigenetic alterations [33, 35]. This is also supported
by the fact that KSHV is a reprogramming virus and the occurrence of host oncogenic alter-
ations in KS lesions [26, 27]. We previously found that KS lesions overexpress Rac1 and that
oxidative stress plays a major role in KS sarcomagenesis [23, 32]. ROS mediated in vivo genetic
damage could lead to accumulation of mutations that could contribute to the viral oncogenesis
process and may compensate for the loss of virus as found in some KS lesions (Fig 5A). The
expression of viral oncoproteins and RNAs may interfere not only with regulators of cell
proliferation, but also with DNA repair mechanisms [33]. We found that cells explanted from
tumors display much more foci of DNA repair which is consistent with increased “in tumor”
DNA damage and DDR (Fig 5B). Genomic instability (GI) is a hallmark of many cancers. This
is probably because ongoing mutations associated with GI increase the frequency of oncogenic
changes that feed natural selection during tumor progression [47].
Analysis of the mutational landscape revealed a set of genes with recurrent mutations in the
exact same position mutated in all six KSHV (+) tumors, but not in the KSHV (+) cell cultures
(Fig 5D). This indicates that in the context of in vivo KSHV infection, tumorigenesis not only
selects for the presence of the virus [21] but also pre-existing host mutations that—as the
KSHV episome—only provide a selective advantage in vivo. Interestingly many of these muta-
tions appear to be in genes regulating viral DNA and innate immunity genes. Some of these
TRIM and IFI family genes, which are IFN inducible genes, have already shown to be
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important for KSHV lytic reactivation [48–50]. It is likely that these mutations allow the
KSHV oncovirus to express oncogenic lytic genes and that they allow for a permissive environ-
ment of inflammatory and viral tumorigenesis, which occurs in the context of DDR that may
be impeded by innate immune DNA sensors.
We found that KSHV oncogenesis also induced the accumulation of a set of de novo muta-
tions that were not present in KSHV (+) cells and KSHV (+) tumors. These mutations were
first selected upon KSHV loss in vitro and would be responsible—together with PDGFRA
D842V— to be driving tumorigenesis compensating KSHV loss (Fig 5D). We recently found
that the most prominent of these mutations is the one activating the KS oncogenic driver
PDGFRA (PDGFRAD842V), that allows the cell to maintain PDGF driven tumorigenesis in
the absence of KSHV [22]. Network analysis of the other de novo mutations (KSHV (-) tumor
associated mutations) points to the existence of a PDGFRA-Rac1 driven network that is con-
sistent with the Rac1 overexpression in AIDS-KS [32] and mECK36 KSHV (+) and KSHV (-)
tumors as well as the proposed role of ROS in AIDS-KS as shown by mECK36 NAC sensitivity
[23].
The direct and “hit and run” virally-induced oncogenic mechanisms proposed through our
modelling in mECK36 cells provide the basis for an additional source of tumor heterogeneity
in KS lesions that may be of clinical importance. The occurrence of host mutations in KS [26,
27] and the existence of variable levels of KSHV-positive cells might be an indication for the
existence of KS spindle cells supported by paracrine mechanisms and/or host oncogenic alter-
nations irreversibly-induced by KSHV. Our results highlight the biological significance of
some of these host mutations such as PDGFRAD842V, a mutation that in GIST is known to
confer resistance to Imatinib, and mutations occurring in innate immune-regulating genes
that were clonally selected during in vivo tumorigenesis pointing to their active role in the
KSHV oncogenic process. Thus, KSHV-induced host mutations within AIDS-KS lesions
could be selected during chemotherapy or targeted therapies and affect their clinical outcomes
[3, 51–54].
In summary, our results have uncovered specific aspects of the interplay between host
oncogenic alterations and virus-induced transcriptional effects, as well as the epigenetic repro-
gramming induced by KSHV infection and tumorigenesis. The existence of virally-induced
irreversible genetic and epigenetic oncogenic alterations underscores the transforming poten-
tial of KSHV infection and supports the possibility of “hit and run” KSHV-sarcomagenesis,
which is consistent with findings of LANA-negative spindle-cells in KS lesions. Our results fur-
ther highlight the potential for the existence of KSHV-induced host mutations that may con-
tribute to the oncogenic process and could be selected upon treatment impacting AIDS-KS
therapies.
Methods
Cell culture and reagents
mECK36, KSHV (+), cells employed in the present study were originated from frozen batches
of mECK36 cells previously generated [21]. KSHV (+) tumors were obtain as previously
shown [21], 1x106 KSHV (+) cells were injected subcutaneously into the flanks of nude mice
and KSHV (+) tumors formed 5 weeks after injection. KSHV (-) cells were used from frozen
populations of KSHV null mECK36 previously obtained after 4 weeks of culturing mECK36
cells without Hygromycin and further selected by weeding and cell sorting [21]. KSHV (-)
tumor cells were obtained from frozen stocks previously generated by explanted mECK36
tumor cells that have lost the Bac36-KSHV episome after 4 weeks of culture without Hygromy-
cin [21]. These KSHV-negative cells were further selected by weeding and cell sorting, and
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characterized thoroughly for KSHV negativity by PCR for LANA, K1, vIRF-1, ORF23, ORF
36, ORF 74, and K15 [23]. KSHV (-) tumors were obtain as previously shown [23], 1x106
KSHV (-) tumor cells were injected subcutaneously into the flanks of nude mice and KSHV (-)
formed tumors 3 weeks after injection.
RNA-Sequencing analysis
RNA was isolated and purified using the RNeasy mini kit (Qiagen). RNA concentration and
integrity were measured on an Agilent 2100 Bioanalyzer (Agilent Technologies). Only RNA
samples with RNA integrity values (RIN) over 8.0 were considered for subsequent analysis.
mRNA from cell lines and tumor samples were processed for directional mRNA-sequencing
library construction using the Preparation Kit according to the manufacturer’s protocol. We
performed paired-end sequencing using an Illumina NextSeq500 platform, all samples were
processed in the same sequencing run of Illumina NextSeq 500 system and analyzed together
with the aim to avoid the batches effect. The short sequenced reads were mapped to the mouse
reference genome (GRCm38.82) by the splice junction aligner TopHat V2.1.0. We employed
several R/Bioconductor packages to accurately calculate the gene expression abundance at the
whole-genome level using the aligned records (BAM files) and to identify differentially
expressed genes between cell lines and cell lines and tumors. Briefly, the number of reads
mapped to each gene based on the TxDb. Mmusculus gene ensembls were counted, reported
and annotated using the Rsamtools, GenomicFeatures, GenomicAlignments packages. To
identify differentially expressed genes between cell lines and tumor samples, we utilized the
DESeq2 test based on the normalized number of counts mapped to each gene. Functional
enrichment analyses were performed using the ClueGo Cytoscape’s plug-in (http://www.
cytoscape.org/) and the InnateDB resource (http://www.innatedb.com/) based on the list of
deregulated transcripts. Data integration and visualization of differentially expressed tran-
scripts were done with R/Bioconductor. KSHV transcriptome was analyzed using previous
resources and KSHV 2.0 reference genome [55], while edgeR test was employed for differential
gene expression analysis of KSHV transcripts.
Methylated DNA Binding Protein sequencing (MBD-sequencing)
Methylated DNA enrichment. Genomic DNA was isolated using DNeasy Blood & Tissue
Kit (QIAGEN) and sheared by sonication to fragments of ~500bp. The sheared DNA (1μg)
was added to 10 μl MBD-Bead slurry (MethylMiner DNA Enrichment Kit, Invitrogen, Carls-
bad, CA) and incubated on a rotating mixer for 1 hr., as described previously [56]. The DNA
fragments were eluted into distinct subpopulations based on the degree of methylation; non-
captured fraction (NC, representing un-methylated DNA fragments), 450 mM NaCl (repre-
senting partially methylated DNA fragments) and 2000 mM NaCl (representing methylated
DNA fragments). The fractions were then ethanol precipitated and re-suspended in H2O.
DNA sequencing and analysis. MBD2 enriched methylated DNA fractions were sub-
jected to library preparation with NEBNext Ultra II DNA library prep kit for Illumina (NEB
#E7645) at the next generation genomic center in the Azrieli Faculty of Medicine, Bar-Ilan
University. The DNA libraries were sequenced on Illumina HiSeq2000, with HiSeq rapid
100PE. Data analysis was performed on the Partek flow platform, raw reads were aligned to
the mouse genome mm10 (GRCm38/mm10) with BWA and more than 80% reads were
uniquely aligned to the reference genome [57]. Mapped reads were analyzed with MACS2 to
generate peaks and annotate differentially methylated regions. Peaks with False discovery rate
(FDR)�5% & Fold change (FC)�2, were considered differentially methylated. When peaks
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were located between 1500 bp upstream and 200 bp downstream of the transcription start site
(TSS), they were considered as differentially methylated gene promoters.
Immunofluorescence staining
Immunofluorescence assay (IFA) was performed as previously described [21]. Cells were fixed
in 4% paraformaldehyde for 10 min and washed with PBS. Cells were permeabilized in 0.2%
Triton-X/PBS for 20 min at 4˚C. After blocking with 3% of BSA in PBS and 0.1% Tween 20 for
60 min, samples were incubated with Primary antibodies overnight at 4C. After PBS washing,
samples were incubated with fluorescent secondary antibodies for 1 hour (Molecular Probes),
washed and mounted with ProLong Gold antifade reagent with DAPI (Molecular Probes).
Images were taken using a Zeiss ApoTome Axiovert 200M microscope.
Animal studies
All mice were housed under pathogen-free conditions. Tumor studies were done in 4- to 6-
week-old nude mice obtained from the National Cancer Institute. Tumors were generated by
subcutaneous injection of mECK36 cells (3 x 105 cells) as previously described [21].
Clinical tissue analysis
Skin KS biopsies were analyzed from an ACSR (The AIDS and Cancer Specimen Resource) tis-
sue microarray. Immunohistochemistry of clinical tissue microarrays was performed using a
standard protocol of the Immunohistochemistry Laboratory of the Department of Pathology
at the University of Miami. Antibody staining of p-PDGFRA from R&D Systems (Minneapo-
lis, MN) was diluted to 1:30 and LANA from Abcam (Cambridge, MA) was diluted 1:40.
Ethics statement
All animal experiments were conducted following NIH guide for the Care and Use of Labora-
tory Animals. The animal experiments have been performed under UM IACUC approval
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Supporting information
S1 Fig. Kaplan-Meier percent tumor-free survival curve from subcutaneous injection of
KSHV (-) tumor cells (N = 3) and KSHV (+) tumors (N = 6).
(TIF)
S2 Fig. KSHV mapped paired reads per million sequenced reads in KSHV (+) cells, KSHV
(+) tumors, KSHV (-) cells and KSHV (-) tumors.
(TIF)
S3 Fig. Immunofluorescence analysis of KSHV LANA (red) in KSHV (+) tumor, nuclei were
counterstained with DAPI (blue).
(TIF)
S4 Fig. Validation of CpG DNA methylation. Enrichment for methylated DNA was per-
formed on MBD2-beads and the proportion of methylaed DNA was determined by qPCR of
the bound versus un-bound fractions for the transition from KSHV(+) cell to KSHV(+) tumor
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(A) or from KSHV(+) tumor to KSHV(-) tumor (B). Three representative gene promoters
were chosen for each transition. Each graph presents results of three biological replicates, n.d
(not detected, all DNA came in the un-methylated fraction). Graphs are presented as means
+ standard deviation, one tailed t tests were performed (�, P� 0.05; ��, P� 0.01; ���;
P� 0.001).
(TIF)
S1 Table. RNA-sequencing and pathways analysis data for gene expression. Tab-A: Differ-
ential expressed genes (DEGs) between KSHV (+) and KSHV (-) cells. Tab-FEA1: pathway
analysis of DEGs in Tab-A. Tab-B: Differential expressed genes (DEGs) between KSHV (+)
tumors and KSHV (+) cells. Tab-FEA2: pathway analysis of DEGs in Tab-B. Tab-C: Differen-
tial expressed genes (DEGs) between KSHV (-) tumor cells and KSHV (-) tumors. Tab-FEA3:
pathway analysis of DEGs in Tab-C. Tab-D: Differential expressed genes (DEGs) between
KSHV (-) tumors and KSHV (+) tumors. Tab-FEA4: pathway analysis of DEGs in Tab-D.
(XLSX)
S2 Table. KSHV (+) cell to KSHV (+) tumor Hypo-methylated.
(XLSX)
S3 Table. KSHV (+) cell to KSHV (+) tumor Hyper-methylated.
(XLSX)
S4 Table. Biological processes and pathways identified in GREAT during the transition
from KSHV (+) cells to KSHV (+) tumors.
(TIF)
S5 Table. Methylation and expression analysis data.
(XLSX)
S6 Table. KSHV (+) tumor to KSHV (-) tumor Hyper-methylated.
(XLSX)
S7 Table. KSHV (+) tumor to KSHV (-) tumor Hypo-methylated.
(XLSX)
S8 Table. Biological processes and pathways identified in GREAT during the transition
from KSHV (+) tumors to KSHV (-) tumors.
(TIF)
S9 Table. Mutational profiles for all samples included in the current study.
(XLSX)
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